title: Targeting P2 receptors--current progress in treating musculoskeletal diseases.
abstract: It is widely recognized that purinergic signalling, extracellular nucleotides acting at purinergic receptors, is the most primitive and ubiquitous signalling system participating in numerous biological processes in almost all tissue types. The P2 receptors, including P2X and P2Y purinoceptor subtypes, have been proposed to play important roles in the musculoskeletal systems since the early 1990s. During the past five years, significant progress in this field has been made; this review will summarize these most recent developments and highlight the pharmaceutical potential from these findings.
authors.affiliation: The Mellanby Centre for Bone Research, Department of Human Metabolism, The University of Sheffield, Sheffield, UK.
authors.forename: Ning
authors.initials: N
authors.lastname: Wang
authors.affiliation: The Mellanby Centre for Bone Research, Department of Human Metabolism, The University of Sheffield, Sheffield, UK. Electronic address: a.gartland@sheffield.ac.uk.
authors.forename: Alison
authors.initials: A
authors.lastname: Gartland
mesh_terms: D000818:Animals; D001842:Bone and Bones / Q000378:metabolism; D002356:Cartilage / Q000378:metabolism; D006801:Humans; D009140:Musculoskeletal Diseases / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism; D018048:Receptors, Purinergic P2 / Q000378:metabolism*
chemical_list: D018048:Receptors, Purinergic P2